ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 08 Feb 2023
Last Updated on 08 Feb 2023
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (DBCd) for inclusion on the MOH List of Subsidised Drugs for treating patients with newly diagnosed light chain (AL) amyloidosis in view of the uncertain extent of clinical benefit and uncertain cost-effectiveness compared with the current treatment option.

Clinical indication, subsidy class and MediShield Life claim limit for daratumumab for AL amyloidosis are provided in the Annex.

Daratumumab for treating newly diagnosed light chain (AL) amyloidosis (Published 8 Feb 2023) PES Daratumumab for treating light chain amyloidosis (Published 8 Feb 2023)